Navigation Links
United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
Date:2/19/2008

rations. The trends for the three-month period ended December 31, 2007, as compared to the same period in 2006, are similar to those noted for the annual period.

The impairment charge during the three months ended December 31, 2007, was primarily related to an other-than-temporary decline of our investment in ViRexx Medical Corp. due to the unsuccessful results of our IMPACT I and II Phase III clinical trials of OvaRex in advanced ovarian cancer.

Stock option expense increased during the three-month and twelve-month periods ended December 31, 2007, over the same periods in 2006, primarily as a result of a stock option grant to our Chief Executive Officer based on the 89% increase in our share price during 2007.

Interest Income. Interest income for the year ended December 31, 2007, was $13.6 million, as compared to interest income of $10.7 million for the year ended December 31, 2006. The difference was due primarily to an increase in market interest rates and amounts available to invest. Interest income for the three months ended December 31, 2007, was comparable to interest income for the same period in 2006.

Income Tax Benefit. We recognized an income tax benefit of approximately $3.3 million and $34.1 million for the years ended December 31, 2007 and 2006, respectively. For the three-month periods ended December 31, 2007 and 2006, we recognized a tax benefit of $7.1 million and $47.7 million, respectively. The tax benefit recognized for 2007 was primarily due to the amount of tax credits generated during the year from our orphan drug related research and development activities. For the year ended December 31, 2006, the tax benefit recognized was primarily due to a reduction of approximately $45.7 million in the valuation allowance against most of our deferred tax assets based on our determination that certain portions of these deferred tax assets are more likely than not realizable.

EBITDASO Calculation

The followi
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. United States Patent Office Grants CryoCors Request for Patent Interference
2. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
3. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
4. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
5. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
6. Neptune Technologies receives GRAS notification in the United States
7. Essilor: New Acquisitions in the United States and Brazil
8. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
9. Medical Services Begins Working With United States Companies for Distribution of Its Products
10. United Therapeutics Reports Third Quarter 2007 Financial Results
11. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 The report ... Management Market by Product Type & Provider ... Analysis (2014-2019)” defines and segments the market ... revenues. , Browse 152 market data ... and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation ... Medtronic, Inc. (NYSE: MDT ) has ... Food and Drug Administration (FDA) for the use ... infusion system (including a newly developed catheter) for ... Injection delivered intravenously to patients with pulmonary arterial ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing ... common stock, and warrants to purchase up to an ... price of $4.00 per share and $.01 per warrant.  ... $5.00, are exercisable immediately, and expire 5 years from ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... 25 Inverness Medical,Innovations, Inc. (Amex: IMA ... products for the consumer and professional markets, announced,today ... Global Healthcare,Unplugged Conference being held April 30 - ... Florida. Ron Zwanziger, Chief Executive Officer, will,attend. His ...
... 25 Abbott,s broad,portfolio of businesses and expanding ... product pipeline provides a,foundation for continued growth as ... Chief Executive Officer Miles D.,White told shareholders today ... an outstanding year for Abbott across all of ...
... -- China Yingxia,International, Inc. (OTC Bulletin Board: ... provider in the nutraceutical industry engaged in ... food,products, supplements, and personal care products in ... that it has formally completed the,acquisition of ...
Cached Biology Technology:Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 2Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 3Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 4China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 3
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... infectious question about eating at restaurants: How clean are ... found that even when they washed dishes in cooler-than-recommended ... levels accepted in the Food and Drug Administration's Food ... milk—can be safe havens for bacteria when dried onto ...
... What influence does the variation in estrogen level ... Using functional Magnetic Resonance Imaging, Jean-Claude Dreher, a ... 1), in collaboration with an American team from ... directed by Karen Berman, has identified, for the ...
... patients who received an new intravenous adult stem cell ... such as cardiac arrhythmias, and had significant improvements in ... received a placebo, according to six-month Phase I study ... in Intervention: i2Summit in New Orleans on March 25. ...
Cached Biology News:Manual dishwashing study digs up dirt on dish cleanliness 2Manual dishwashing study digs up dirt on dish cleanliness 3The influence of the menstrual cycle on the female brain 2The influence of the menstrual cycle on the female brain 3The influence of the menstrual cycle on the female brain 4Stem cell therapy shows promise in regenerating damaged muscle in heart attack patients 2